Predicting GBM response to targeted therapeutics using simulation with ex vivo validations

Background: The unique signature of a patient’s tumor implies that a one-size-fits-all treatment approach will likely fail. This necessitates a rationally designed personalized therapeutic approach employing N=1 segmentation.